Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
Would you consider nivolumab/relatlimab as a salvage therapy option for advanced melanoma patients who progressed on single-agent PD-1 inhibitor?
Related Questions
How do you approach patients with stage III melanoma for adjuvant treatment?
How would you approach patients receiving neoadjuvant pembrolizumab (SWOG 1801) for melanoma with no response to systemic treatment?
How do you approach patients with metastatic uveal melanoma not a candidate for tebentafusp-tebn?
What criteria do you use to determine the resectability of mucosal melanoma of the H&N region?
What scenario would prophylactic Tocilizumab be considered to prevent Ipilimumab+Nivolumab (immunotherapy) induced toxicity in malignant melanoma?
How do you approach patients with recurrent BRAF negative melanoma and resected oligo-metastasis after completing one year of adjuvant nivolumab?
Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?
How would you approach a 2 cm malignant primary cutaneous adnexal adenocarcinoma of the axilla s/p resection with positive margin who is unable to undergo additional surgery?
Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?
What systemic therapy would you offer a patient with metastatic melanoma who is BRAF WT and developed metastases while on adjuvant nivolumab?